Haleon (HLN)
undefined
undefined%
At close: undefined
9.46
0.05%
After-hours Jan 03, 2025, 04:00 PM EST

Company Description

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.

Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum.

The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022.

Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Haleon
Haleon logo
Country GB
IPO Date Jul 25, 2022
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 25,408
CEO Brian James McNamara

Contact Details

Address:
Building 5
Weybridge,
GB
Website https://www.haleon.com

Stock Details

Ticker Symbol HLN
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001900304
CUSIP Number 405552100
ISIN Number US4055521003
Employer ID 00-0000000
SIC Code 2844

Key Executives

Name Position
Brian James McNamara Chief Executive Officer & Executive Director
Dawn Amanda Allen Chief Financial Officer & Director
Tamara Rogers Chief Marketing Officer
Adrian Charles Morris General Counsel
Claire Dickson Chief Digital & Technology Officer
Filippo Lanzi President of EMEA & LatAm
Keith Choy President of Asia Pacific
Line De Decker Chief Human Resources Officer
Sonya Ghobrial Head of Investor Relations
Tobias Hannes Hestler Executive Officer

Latest SEC Filings

Date Type Title
Dec 31, 2024 6-K Filing
Dec 19, 2024 6-K Filing
Dec 13, 2024 6-K Filing
Dec 11, 2024 6-K Filing
Dec 11, 2024 6-K Filing
Dec 10, 2024 6-K Filing
Dec 05, 2024 6-K Filing
Nov 29, 2024 6-K Filing
Nov 27, 2024 6-K Filing
Nov 26, 2024 6-K Filing